

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA

ABBOTT DIABETES CARE INC. and
ABBOTT LABORATORIES,

Plaintiffs,

vs.

ROCHE DIAGNOSTICS CORPORATION
and BAYER HEALTHCARE LLC

Defendant.

CASE NO. C05-3117 MJJ

PROTECTIVE ORDER

GRANTED

Pursuant to Fed. R. Civ. P. 26(c), by agreement of Abbott Diabetes Care Inc. (“ADC”), Abbott Laboratories (“Abbott”) (collectively, “Plaintiffs”), and Defendants Roche Diagnostics Corporation (“RDC”), Roche Diagnostics Operations, Inc. (“RDOI”), and Bayer Healthcare LLC (“Bayer”) (hereinafter individually referred to as a “party” or collectively as “the parties”), the Court finds that good cause exists for entry of a protective order to prevent unauthorized disclosure and use of the parties’ trade secrets and other confidential information during and after the course of this litigation. Accordingly, IT IS HEREBY ORDERED THAT:

1. This Stipulation and Order governs the treatment of documents, transcripts of and exhibits to depositions, interrogatory answers, responses to requests for admissions, correspondence, and other written, recorded, or graphic material, including all copies, excerpts, abstracts, or summaries thereof, and any physical objects or other items or any other information gained by inspection of any tangible thing, including data or code stored in electronic form (collectively, “Material”), produced, filed with the Court, served by, or obtained from any party or non-party to this action (collectively, “Person(s)”).

2. Any Person shall have the right, before disclosure to other parties, to designate as “CONFIDENTIAL” or “HIGHLY CONFIDENTIAL” any Material it produces or provides that constitutes, reflects or discloses its trade secrets or other confidential research, development, or commercial information within the scope of Rule 26(c)(7) of the Federal Rules of Civil Procedure, subject to the further limitations enumerated in this Protective Order.

A. Definitions

3. The terms “Confidential Information” and “Highly Confidential Information” shall include all information, documents and other materials revealed or disclosed during the proceedings and trial of the above matter that are designated as “Confidential Information” or “Highly Confidential” as set forth in the next two paragraphs.

4. “Confidential Information” shall mean material that a party claims in good faith contains or discloses information relating to, referencing or pertaining to trade secrets or other confidential research, development or commercial information that is properly subject to

1 protection under Federal Rule of Civil Procedure 26(c), including but not limited to any party's
 2 technical information relating to blood glucose test strips and monitoring devices, and methods of
 3 producing the same. These documents include, but are not limited to, non-public experiments,
 4 technical documents, lab notebooks, financial records, market information, and marketing
 5 material. Counsel shall not designate any discovery material "CONFIDENTIAL" without first
 6 making a good faith determination that such protection is warranted.

7 5. "Highly Confidential Information" shall mean discovery materials that qualify as
 8 "Confidential Information" pursuant to the definition in paragraph A. 4. above, AND that are of
 9 such sensitivity that a party reasonably believes that their disclosure to the adversary could harm
 10 its business, such as customer, licensee, supplier and vendor information, financial or marketing
 11 information (including past information indicative of current practices), business plans or
 12 competitive strategies, information relating to research, development, chemical composition,
 13 testing, and manufacturing, or software algorithms, or information relating to pending or
 14 abandoned patent applications which have not been made available to the public. These
 15 documents include, but are not limited to, "future" documents such as unfiled patents, developing
 16 technologies, and marketing and business plans and "current" company documents such as
 17 current pricing and financial information, current marketing plans, current research and
 18 development, and current customer, distributor, licensee, supplier, and vendor information.
 19 Counsel shall not designate any discovery material "HIGHLY CONFIDENTIAL" without first
 20 making a good faith determination that such protection is warranted.

21 B. **Designation of Confidential Information**

22 6. If an exhibit, pleading, interrogatory answer or admission (collectively "discovery
 23 response"), document or thing (collectively "document or thing") or a deposition transcript, other
 24 transcript of testimony or declaration or affidavit (collectively "testimony") contains information
 25 determined in good faith to be confidential by a Person, such exhibit, pleading, discovery
 26 response, document or thing, or testimony shall be designated "Confidential" or "Highly
 27 Confidential" by the Person contending there is confidential information therein. If an exhibit,
 28

1 pleading, discovery response, document or thing, testimony or other court submission contains
 2 information designated by a Person as "Confidential" or "Highly Confidential," the words
 3 "CONFIDENTIAL" or "HIGHLY CONFIDENTIAL" shall be affixed thereto before production
 4 or service.

5 7. A Person may designate information disclosed during a deposition or other
 6 testimony as "Confidential" or "Highly Confidential," either by (a) designating on the record that
 7 all or specific portions of the deposition transcript, and the information contained therein, is to be
 8 treated as "Confidential" or "Highly Confidential"; or (b) designating in writing, within thirty
 9 (30) days after receipt of the testimony, specific portions of the testimony that should be so
 10 designated. Unless otherwise agreed on the record of the deposition or other testimony, all
 11 transcripts shall be treated as "Highly Confidential" for a period of thirty (30) days after their
 12 receipt, and the transcript shall not be disclosed by a non-designating party to persons other than
 13 those persons named or approved according to paragraph 11 to review documents or information
 14 designated "Highly Confidential" on behalf of that non-designating party. For such time as any
 15 information or documents designated "CONFIDENTIAL" or "HIGHLY CONFIDENTIAL" are
 16 disclosed in a deposition or Court proceeding, the Person whose information or documents are to
 17 be disclosed shall have the right to exclude from attendance at the deposition or Court proceeding
 18 any person who is not entitled to receive such information or documents pursuant to this Order.

19 8. All documents, or any portion thereof, produced for inspection only (i.e., copies
 20 have not yet been provided to the receiving party) shall be deemed "Highly Confidential." If a
 21 copy of any such document is requested after inspection, the document shall only be deemed
 22 "Confidential" or "Highly Confidential" if labeled or marked in conformity with this Protective
 23 Order.

24 **C. Use of Confidential Information**

25 9. Except upon the prior written consent of the designating Person, or upon further
 26 Order of this Court, Confidential Information or Highly Confidential Information shall be treated
 27 strictly in accordance with the provisions of this Protective Order and may be used or disclosed
 28

only as specified in this Protective Order. Further, where required in paragraphs 10 and 11 below, no Confidential Information or Highly Confidential Information shall be disclosed to any person until he/she has signed a copy of the Non-Disclosure and Confidentiality Agreement, which is attached as Exhibit A to this Protective Order.

10. Access to information marked CONFIDENTIAL shall be limited to:

(a) Outside counsel for the respective parties to this litigation, including persons working in secretarial, clerical and paralegal capacities who are providing assistance to outside counsel.

(b) The following ADC and Abbott in-house counsel: Karen L. Hale (Division Counsel, Intellectual Property Litigation), Nicholas Poulos (Divisional Vice President and Section Head, Intellectual Property Litigation), and José Rivera, (Divisional Vice President and Associate General Counsel, Intellectual Property Litigation), and clerical staff assisting said individuals in the prosecution or defense of this action following the production of declaration establishing that Ms. Hale, Mr. Poulos, and Mr. Rivera are not involved in competitive decision-making for blood glucose products. ADC or Abbott may, as necessary, request the substitution or addition of and RDC, RDOI, and Bayer may request the addition of other lawyers who are not involved in competitive decision-making for blood glucose products, and consent will not unreasonably be withheld following the production of a declaration establishing that the lawyer is not involved in competitive decision-making for blood glucose products. For purposes of this Order, "competitive decision-making" does not include advice that in-house counsel provides to his or her client regarding designing around a patent.

(c) Witnesses in any deposition or other proceedings of this litigation who (i) at the time of such proceeding, are current employees of the producing Person, (ii) are the author or recipient of the information marked Confidential, or (iii) based on evidence, are reasonably believed to have had access to the "Confidential" information in the past. Notwithstanding the foregoing, the questioning attorney may show the document to a witness who is a former employee of the producing Person but who is not employed or retained by the party opposed to

1 the producing Person at the time of the examination, solely for the purpose of asking the witness
2 preliminary questions to determine authorship, receipt, or access to the information marked
3 "Confidential." If the witness testifies that he or she did not author, receive, or have access to the
4 information marked "Confidential," the information marked "Confidential" will be removed from
5 the witness' view.

6 (d) Independent outside experts and consultants (and their employees or
7 clerical assistants) who are employed, retained or otherwise consulted by outside counsel of
8 record to assist in any way in the preparation and trial of this action; provided, however, that at
9 least seven business days before such person is given access to any confidential information, the
10 party retaining such expert or consultant shall provide the opposing party with (i) the current title
11 and employer of the expert, translator, or consultant; (ii) his or her current resume; and (iii) an
12 undertaking signed by the expert or consultant in the form attached here to as Exhibit A to abide
13 by the terms of this protective order. A separate disclosure and undertaking is not required for
14 staff assisting any such expert or consultant. For purposes of this Protective Order, the phrase
15 "outside experts or consultants" shall not include any current or former officer, director or
16 employee of any party.

17 (e) Court personnel in the conduct of their official duties, and the trier of fact.

18 (f) Qualified persons taking testimony involving Confidential Information and
19 necessary stenographic, videographic, and clerical personnel thereof.

20 (g) Duplicating services, translators, litigation support services and other
21 auxiliary services of a like nature, routinely engaged by counsel.

22 11. Access to information marked HIGHLY CONFIDENTIAL shall be limited to:

23 (a) Outside counsel for the respective parties to this litigation, including
24 persons working in secretarial, clerical and paralegal capacities who are providing assistance to
25 outside counsel;

26 (b) Witnesses in any deposition or other proceeding of this litigation who
27 either (i) are the author or recipient of the information marked "Highly Confidential," or (ii)

28

1 based on the evidence, have had access to the "Highly Confidential" information in the past.
 2 Notwithstanding the foregoing, the questioning attorney may show the document to a witness
 3 who is a current employee of the producing Person, or a former employee of the producing
 4 Person but who is not employed or retained by the party opposed to the producing Person at the
 5 time of the examination, solely for the purpose of asking the witness preliminary questions to
 6 determine authorship, receipt, or access to the information marked "Highly Confidential." If the
 7 witness testifies that he or she did not author, receive, or have access to the information marked
 8 "Highly Confidential," the information marked "Highly Confidential" will be removed from the
 9 witness' view.

10 (c) Independent outside experts and consultants (and their employees or
 11 clerical assistants) who are employed, retained or otherwise consulted by outside counsel of
 12 record to assist in any way in the preparation and trial of this action; provided, however, that at
 13 least seven business days before such person is given access to any confidential information, the
 14 party retaining such expert or consultant shall provide the opposing party with (i) the current title
 15 and employer of the expert, translator, or consultant; (ii) his or her current resume; and (iii) an
 16 undertaking signed by the expert or consultant in the form attached here to as Exhibit A to abide
 17 by the terms of this protective order. A separate disclosure and undertaking is not required for
 18 staff assisting any such expert or consultant. For purposes of this Protective Order, the phrase
 19 "outside experts or consultants" shall not include any current or former officer, director or
 20 employee of any party.

21 (d) Court personnel in the conduct of their official duties, and the trier of fact.
 22 (e) Qualified persons taking testimony involving Confidential Information and
 23 necessary stenographic, videographic, and clerical personnel thereof.

24 (f) Duplicating services, translators, litigation support services and other
 25 auxiliary services of a like nature, routinely engaged by counsel.

26 (g) The following ADC or Abbott in-house counsel: Karen L. Hale (Division
 27 Counsel, Intellectual Property Litigation), Nicholas Poulos (Divisional Vice President and
 28

1 Section Head, Intellectual Property Litigation), and José Rivera (Divisional Vice President and
 2 Associate General Counsel, Intellectual Property Litigation), and clerical staff assisting said
 3 individuals in the prosecution or defense of this action, provided that the identified counsel
 4 produce declarations establishing that they (1) are not involved in competitive decision-making or
 5 the development or marketing of any blood glucose product and (2) are not and will not be
 6 involved in the prosecution of any patents relating to blood glucose testing from the date this
 7 Protective Order is entered until thirty-six (36) months after judgment is entered in the above-
 8 captioned action. ADC or Abbott may, as necessary, request to substitute or add and RDC,
 9 RDOI, and Bayer may request to add inside counsel, provided that the lawyer produces a
 10 declaration establishing that (1) the lawyer is not involved in competitive decision-making or the
 11 development or marketing of any blood glucose product and (2) is not and will not be involved in
 12 the prosecution of any patents relating to blood glucose testing from the date this Protective Order
 13 is entered until thirty-six (36) months after judgment is entered in the above-captioned action.

14 12. Notwithstanding and in addition to the limitations placed upon access to
 Confidential and Highly Confidential information set forth in the preceding paragraphs, the
 15 persons set forth in the protective order entered in Case Nos. C04-2123 MJJ/BZ; C04-3327
 MJJ/BZ; C04-3732 MJJ/BZ; and in this action may access Confidential and Highly Confidential
 16 Information produced by all parties in this action, and such materials will be treated as if
 17 designated under the Protective Order in those cases as to those persons. No party to any case
 18 referenced in this paragraph shall deliver to any other party any document marked Confidential or
 19 Highly Confidential except in the context of depositions, discovery responses, hearings, or court
 20 filings in any case referenced in this paragraph; or if, after 10 days written notice to the producing
 21 party, the producing party does not object; or by agreement.

22 13. If, pursuant to this Order, a party identifies a person as an expert, consultant, or
 advisor, no other party shall contact the person nor subject the expert to discovery to inquire into
 23 matters arising within the expert's consultation with the designating party, except as provided by
 24 Federal Rule of Civil Procedure 26(b)(4) or by Order of the Court.

25
 26
 27
 28

1 **D. Filing Under Seal**

2 14. A party wishing to file any pleading or other document that contains Confidential
 3 Information or Highly Confidential Information designated by any other Person must place
 4 documents containing Confidential Information or Highly Confidential Information in a sealed
 5 envelope with instructions to the Clerk that (a) the document is filed pursuant to the Stipulated
 6 Protective Order; and (b) the envelope is not to be opened absent further order of the Court. The
 7 envelope should be labeled to identify the title of the case, case number, and the title of the
 8 document. In addition to these requirements, parties must also follow the procedures for filing
 9 documents under seal set forth in Northern District of California Local Rule 79-5.

10 **E. Inadvertent Production, Redactions and Failures to Designate.**

11 15. Notwithstanding anything contrary herein, if a Person through inadvertence or
 12 mistake fails to designate or produces discovery of any Confidential Information without marking
 13 it with the legend CONFIDENTIAL or HIGHLY CONFIDENTIAL, or designates it with an
 14 incorrect level of confidentiality, the producing Person may give written notice to the receiving
 15 party, within 10 days of discovery of the inadvertent designation or production, that the exhibit,
 16 pleading, discovery response, document or thing, or testimony contains Confidential Information
 17 or Highly Confidential Information and should be treated as such in accordance with the
 18 provisions of this Protective Order. Upon receipt of such timely notice, and upon receipt of
 19 properly marked materials, the receiving party shall return or destroy said unmarked materials
 20 and not retain copies thereof, and must treat such exhibits, pleadings, discovery responses,
 21 documents or things, or testimony as Confidential Information or Highly Confidential
 22 Information, as the case may be, and shall cooperate in restoring the confidentiality of such
 23 Confidential or Highly Confidential Information. The inadvertent or unintentional disclosure by a
 24 Person of Confidential or Highly Confidential Information, regardless of whether the information
 25 was so designated at the time of disclosure, shall not be deemed a waiver in whole or in part of a
 26 Person's claim of confidentiality either as to the specific information disclosed or as to any other
 27 information relating thereto or on the same or related subject matter, provided that the non-

1 producing party is notified and properly marked documents are supplied as provided herein. The
 2 receiving party shall not be responsible for the disclosure or other distribution of belatedly
 3 designated Confidential or Highly Confidential Information as to such disclosure or distribution
 4 that may occur before the receipt of such notification of a claim of confidentiality and such
 5 disclosure or distribution shall not be deemed to be a violation of this Protective Order.

6 16. Documents and things produced or made available for inspection may be subject
 7 to redaction, in good faith by the producing Person, of information that is subject to the attorney-
 8 client privilege, work-product immunity or any other privilege. Each such redaction, regardless
 9 of size, will be clearly labeled. This paragraph shall not be construed as a waiver of any party's
 10 right to seek disclosure of redacted information. The basis for any redaction based upon a claim
 11 of attorney-client privilege or work-product immunity shall be listed on a privilege log.

12 17. The inadvertent or unintentional production of any document or thing by any
 13 Person shall be without prejudice to any claim by the producing Person that such material is
 14 protected by the attorney client privilege or protected from discovery as work product or under
 15 another applicable privilege or doctrine, and no Person shall be held to have waived any rights
 16 thereunder by inadvertent or unintentional production. If within ten (10) days after discovering
 17 the inadvertent or unintentional production of the documents, a producing Person asserts that such
 18 documents are protected by the attorney client privilege, work product doctrine, or other
 19 applicable privilege or doctrine and were inadvertently or unintentionally produced, the receiving
 20 party shall take prompt steps to ensure that all known copies of such documents are returned
 21 promptly to the producing Person. The parties may thereafter contest such claims of privilege or
 22 work product as if the materials had not been produced but shall not assert that a waiver occurred
 23 as a result of the production. The receiving party shall not use any of the information contained
 24 in the inadvertently or unintentionally produced materials.

25 F. **Challenging "CONFIDENTIAL" or "HIGHLY CONFIDENTIAL" Designations**

26 18. There shall be no obligation to challenge a Confidential Information or Highly
 27 Confidential Information designation when made and failure to do so shall not preclude a

1 subsequent challenge.

2 19. Any party who objects to the designation of any information as "Confidential" or
 3 "Highly Confidential" or objects to a restriction on the use of such Confidential Information or
 4 Highly Confidential Information may apply to this Court for a ruling that the information or
 5 material shall not be so designated. The burden of proof shall be on the party seeking protection
 6 of the information to show that protection of such information under this Protective Order is
 7 warranted. Unless and until the Court determines that protection under this Protective Order is
 8 not warranted, the information shall continue to be treated as Confidential Information or Highly
 9 Confidential Information.

10 **G. Miscellaneous Provisions**

11 20. In the event any of the parties (a) is subpoenaed in another action, or (b) is served
 12 with a demand in another action to which it is a party, or (c) is served with any other legal process
 13 by a person not a party to this litigation, and is requested to produce or otherwise disclose
 14 information that was designated as Confidential Information or Highly Confidential Information
 15 by a Person in this action, the party subpoenaed or served as referred to in this paragraph shall
 16 object to production of the Confidential Information or Highly Confidential Information and shall
 17 give prompt written notice to the designating Person with sufficient time to afford the designating
 18 Person to intervene. The notice shall include a copy of any such subpoena, demand, or other
 19 process. Should the person seeking access to the Confidential Information or Highly Confidential
 20 Information take action against the party covered by this Protective Order to enforce such a
 21 subpoena, demand or other legal process, it shall respond by setting forth the existence of this
 22 Protective Order. Nothing in this Order shall be construed as requiring the party covered by this
 23 Protective Order to challenge or appeal any order requiring production of Confidential
 24 Information or Highly Confidential Information covered by this Protective Order, to subject itself
 25 to any penalties for noncompliance with any legal process or order, or to seek any relief from this
 26 Court.

27 21. This Order shall not abrogate or diminish any contractual, statutory, or other legal
 28

1 obligation or right of any party to this Order, as to any third party, with respect to any
 2 Confidential Information.

3 22. Nothing in this Protective Order shall be construed as a finding that any designated
 4 Confidential Information or Highly Confidential Information actually constitutes or contains
 5 proprietary or confidential material or trade secrets. For purposes of this order, proprietary or
 6 confidential information or trade secrets shall not include information or material that:

7 (a) was, is or becomes public knowledge in a manner other than by violation
 8 of this Order;

9 (b) is acquired by the non-designating party from a third party having the right
 10 to disclose voluntarily such information or material;

11 (c) was lawfully possessed by the non-designating party prior to the entry of
 12 this Order by the Court; or

13 (d) was developed by the non-designating party independent of the information
 14 produced under the Protective Order.

15 23. Nothing in this Protective Order shall bar or otherwise restrict any attorney for the
 16 parties from rendering advice to his or her client with respect to this action. In the course of
 17 doing so, said attorney may generally refer to or rely upon his or her examination of Confidential
 18 Information or Highly Confidential Information, but shall not disclose the specific contents of
 19 Confidential Information or Highly Confidential Information to persons not authorized to receive
 20 such Confidential Information or Highly Confidential Information pursuant to this Protective
 21 Order except by written agreement with counsel for the designating Person.

22 24. The terms of this Protective Order are applicable to Confidential Information
 23 produced by a non-party, and a party or a non-party may designate Material produced in
 24 connection with this litigation as Confidential Information or Highly Confidential Information.
 25 Such Information so designated will be protected by the remedies and relief provided by the
 26 Protective Order.

27 25. Upon the settlement or exhaustion of all appeals in this action ("Conclusion of this
 28

1 Litigation"), all persons to whom Confidential Information or Highly Confidential Information
 2 has been disclosed shall, without demand, either (a) destroy, or (b) return to the Person that
 3 originally produced it, all Confidential Information or Highly Confidential Information (and all
 4 copies of such material) and all other documents containing information taken from the
 5 Confidential Information or Highly Confidential Information within sixty (60) days of the
 6 Conclusion of this Litigation, except that each party's litigation counsel may retain copies of
 7 pleadings, briefs, motions and the like actually filed in court that include Confidential Information
 8 or Highly Confidential Information, and each party's litigation counsel may retain one complete
 9 copy of any outside counsel work files containing Confidential or Highly Confidential
 10 information. Upon written request, all recipients of Confidential Information or Highly
 11 Confidential Information shall certify in writing that they have complied with the provisions of
 12 this paragraph.

13 26. Upon the Conclusion of this Litigation:

14 (e) any Confidential Information or Highly Confidential Information produced
 15 hereunder that has been submitted for identification or into evidence at any hearing or trial in this
 16 litigation may be withdrawn by counsel for the person who offered such Confidential Information
 17 or Highly Confidential Information into evidence;

18 (f) the Clerk is authorized to deliver said Confidential Information or Highly
 19 Confidential Information to said counsel;

20 (g) any such Confidential Information or Highly Confidential Information not
 21 returned to counsel shall be destroyed.

22 27. Nothing in this Order shall be deemed a waiver of any right any party otherwise
 23 might have under the Federal Rules or the doctrines of attorney-client privilege or attorney work
 24 product. This Protective Order shall survive the Conclusion of this Litigation and continue in full
 25 force and effect. The Court shall retain jurisdiction to enforce this Protective Order for a period
 26 of six (6) months after the final termination of the action.

27 28. By entering this order and limiting the disclosure of information in this case, the

28

1 Court does not intend to preclude another court from finding that information may be relevant and
2 subject to disclosure in another case.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1
2 IT IS SO ORDERED.
3

4 DATED: MAY 30, 2006
5



Honorable Martin J. Jenkins

UNITED STATES DISTRICT COURT JUDGE

6
7
8
9
10 IT IS SO STIPULATED.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1

BAKER BOTTS LLP

2

By:

James W. Cannon, Jr.

3

4

5

ABBOTT LABORATORIES

6

By:

Karen L. Hale

7

8

9

By:

Nicholas A. Poulos

10

11

12

By:

José E. Rivera

13

14

Attorneys for Plaintiffs Abbott Diabetes Care Inc.
and Abbott Laboratories

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1 BARNES & THORNBURG LLP
2

3 By: _____
4

Donald E. Knebel
Lynn C. Tyler

5 *Attorneys for Defendants Roche Diagnostics*
6 *Corporation and Roche Diagnostics Operations,*
7 *Inc.*

8 MORRISON FOERSTER
9

10 By: _____
11 Wesley E. Overton


12 *Attorneys for Defendant Bayer Healthcare LLC*
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 BARNES & THORNBURG LLP
2

3 By: _____
4 Donald E. Knebel
Lynn C. Tyler
5

6 *Attorneys for Defendants Roche Diagnostics*
7 *Corporation and Roche Diagnostics Operations,*
8 *Inc.*

9 MORRISON & FOERSTER LLP
10

11 By: 
Wesley E. Overson
12

13 *Attorneys for Defendant Bayer Healthcare LLC*
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

1 EXHIBIT A
23 **NON-DISCLOSURE AND CONFIDENTIALITY AGREEMENT**

4 The undersigned hereby acknowledges that (s)he has read the Protective Order
5 entered on _____, in the above-captioned action, and understands the terms
6 thereof, and agrees, upon threat of penalty of contempt, to be bound by such terms of each
7 paragraph of the Protective Order. In particular, the undersigned understands that the terms of
8 said Protective Order obligate him/her to use Confidential Information or Highly Confidential
9 Information solely for the purposes of this litigation and to not disclose any such Confidential
10 Information or Highly Confidential Information to any other person, firm or entity, except that
11 there will be no restriction on documents that are used as exhibits in Court, unless such exhibits
12 were filed under seal, and there will be no restriction on information disclosed in open Court,
13 unless the Courtroom is sealed at the time of such disclosure. Further, the undersigned hereby
14 agrees to subject himself/herself to the jurisdiction of this Court if any dispute arises regarding
15 his/her use of Confidential Information or for the purpose of otherwise enforcing this Non-
16 Disclosure and Confidentiality Agreement.

17

18

19

Date

Signature

20

21

22

23

24

25

26

27

28